On Monday, Following Stocks were among the “Top 100 Gainers” of U.S. Stock Market: EQT Corporation (NYSE:EQT), Hyperion Therapeutics, Inc. (NASDAQ:HPTX), ImmunoGen, Inc. (NASDAQ:IMGN), Marathon Petroleum Corporation (NYSE:MPC)
EQT Corporation (NYSE:EQT), with shares gained 3.28%, closed at $82.70.
Hyperion Therapeutics, Inc. (NASDAQ:HPTX), with shares jumped 7.58%, settled at $45.98.
ImmunoGen, Inc. (NASDAQ:IMGN), with shares climbed 3.27%, and closed at $8.52.
Marathon Petroleum Corporation (NYSE:MPC), surged 3.26%, and closed at $102.90.
Latest NEWS regarding these Stocks are depicted underneath:
EQT Corporation (NYSE:EQT)
Formerly on March 11, EQT Corporation (EQT), and EQT Midstream Partners, LP (EQM), declared the pricing of 8,250,000 ordinary units representing limited partner interests at $76.00 per ordinary unit. EQT Midstream Partners, LP (Partnership) has granted the underwriters a 30-day option to purchase up to an additional 1,237,500 ordinary units.
The Partnership intends to use the net proceeds from the offering to fund a portion of the purchase price for the attainment of the Northern West Virginia Marcellus Gathering System and a preferred interest in an EQT partner.
The Partnership intends to use the net proceeds from the underwriters’ exercise of their option to purchase additional ordinary units, if any, counting any proportionate capital contribution from the Partnership’s general partner to maintain its 2% general partner interest in the Partnership, for general partnership purposes.
EQT Corporation, together with its auxiliaries, operates as a natural gas corporation in the United States. It operates in two segments, EQT Production and EQT Midstream. The EQT Production segment explores for, in addition to develops and produces natural gas, natural gas liquids (NGLs), and crude oil primarily in the Appalachian Basin.
Hyperion Therapeutics, Inc. (NASDAQ:HPTX)
Hyperion Therapeutics, Inc. (HPTX), and Horizon Pharma plc (NASDAQ:HZNP), declared they have reached a definitive contract under which Horizon Pharma will attain all of the issued and outstanding shares of Hyperion’s ordinary stock for $46.00 per share in cash or about $1.1 billion on a fully diluted basis. The per share consideration represents a premium of about 35 percent to Hyperion’s volume weighted average price for the trailing 60-days. The projected transaction has been unanimously approved by both companies’ boards of directors.
“The Hyperion attainment will expand and diversify our product portfolio by adding two complementary orphan disease products, RAVICTI and BUPHENYL, and leverage in addition to expand the existing infrastructure of our orphan disease business,” said Timothy P. Walbert, chairman, president and chief executive officer, Horizon Pharma plc. “This transaction will be right away accretive to adjusted EPS and we expect the contribution of RAVICTI and BUPHENYL in 2016 will add about $100 million to our adjusted EBITDA, counting cost synergies contributing greater than $50 million. Additionally, this attainment further accelerates our near- and long-term sales and adjusted EBITDA growth and provides noteworthy value for both Horizon and Hyperion shareholders.”
Hyperion Therapeutics, Inc., a biopharmaceutical corporation, focuses on the development and commercialization of therapeutics to treat orphan diseases in the United states, Canada, and internationally.
ImmunoGen, Inc. (NASDAQ:IMGN)
ImmunoGen, Inc. (IMGN), declared a $200 million non-dilutive royalty transaction with funds managed by TPG Special Situations Partners (“TSSP”).
In return for the payment to ImmunoGen, TSSP will have the right to receive 100% of the royalty proceed on Kadcyla® commercial sales that would otherwise be paid by Roche to ImmunoGen until TSSP has received a total of either $235 million or $260 million, depending on timing. After this threshold is met, if ever, ImmunoGen will receive 85% of the Kadcyla royalty proceed and TSSP will receive 15% of the Kadcyla royalty proceed until this proceed stream ends. The transaction is subject to the satisfaction of customary closing conditions and is predictable to close in early April 2015.
ImmunoGen had about $107 million in cash and cash equivalents as of December 31, 2014. The transaction declared recently is predictable to yield net proceeds to ImmunoGen of about $194 million.
ImmunoGen, Inc., a biotechnology corporation, develops targeted anticancer therapeutics. It develops its products using its antibody-drug conjugates technology. The corporation offers Kadcyla, an antibody-drug conjugate for the treatment of HER2-positive metastatic breast cancer.
Marathon Petroleum Corporation (NYSE:MPC)
Marathon Petroleum Corporation (MPC), declared that it will host a conference call on Thursday, April 30, at 10 a.m. EDT to provide an update on corporation operations and to talk about 2015 first-quarter financial results, which will be released earlier that day.
MPC participants will be Gary Heminger, president and chief executive officer; Don Templin, executive vice president of Supply, Transportation and Marketing; Tim Griffith, senior vice president and chief financial officer; and Mike Palmer, senior vice president of Supply, Distribution and Planning. The call will be hosted by Geri Ewing, director of investor relations.
MPC is the nation`s fourth-largest refiner, with a crude oil refining capacity of about 1.7 million barrels per calendar day in its seven-refinery system. Marathon brand gasoline is sold through about 5,460 independently owned retail outlets across 19 states.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
